PA8598901A1 - QUINOLINE AND QUINOXALINE COMPOUND - Google Patents
QUINOLINE AND QUINOXALINE COMPOUNDInfo
- Publication number
- PA8598901A1 PA8598901A1 PA20048598901A PA8598901A PA8598901A1 PA 8598901 A1 PA8598901 A1 PA 8598901A1 PA 20048598901 A PA20048598901 A PA 20048598901A PA 8598901 A PA8598901 A PA 8598901A PA 8598901 A1 PA8598901 A1 PA 8598901A1
- Authority
- PA
- Panama
- Prior art keywords
- quinoline
- compounds
- plesterol
- levels
- cholesterol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPUESTOS DE QUINOLINA Y QUINOXALINA, COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES COMPUESTOS Y EL USO DE TALES COMPUESTOS PARA AUMENTAR CIERTOS NIVELES DE LIPIDOS EN EL PLASMA, INCLUYENDO LA LIPOPROTEINA DE ALTA DENSIDAD DEL COLESTEROL Y PARA REDUCIR OTROS NIVELES DE LIPIDOS EN PLASMA, TALES COMO COLESTEROL LDL Y TRIGLICERIDOS, Y POR CONSIGUIENTE, PARA TRATAR ENFERMEDADES QUE SE VEN AFECTADAS POR LOS NIVELES BAJOS DE COLESTEROL HDL Y/O NIVELES ALTOS DE COLESTEROL-LDL Y TRIGLICERIDOS, TALES COMO ATEROSCLEROSIS Y ENFERMEDADES CARDIOVASCULARES EN CIERTOS MAMIFEROS, INCLUYENDO SERES HUMANOS.QUINOLINE AND QUINOXALINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS AND THE USE OF SUCH COMPOUNDS TO INCREASE CERTAIN LEVELS OF LIPIDS IN THE PLASMA, INCLUDING HIGH DENSITY LIPOPROTEIN OF COLESTEROL OR PLESTEROL NETWORKS IN PLESTEROL OR LIVESTROLES AND TRIGLICERED, AND THEREFORE, TO TREAT DISEASES THAT ARE AFFECTED BY THE LOW LEVELS OF CHOLESTEROL HDL AND / OR HIGH LEVELS OF CHOLESTEROL-LDL AND TRIGLYCERED, SUCH AS ATEROSCLEROSIS AND MULTI-VARIOUS CARDIOVASCULAR CUSTOMS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45827403P | 2003-03-28 | 2003-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8598901A1 true PA8598901A1 (en) | 2004-11-26 |
Family
ID=33098266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20048598901A PA8598901A1 (en) | 2003-03-28 | 2004-03-26 | QUINOLINE AND QUINOXALINE COMPOUND |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1622872A1 (en) |
JP (1) | JP2006521344A (en) |
KR (1) | KR100729883B1 (en) |
CN (1) | CN1795177A (en) |
AR (1) | AR044507A1 (en) |
AU (1) | AU2004224082A1 (en) |
BR (1) | BRPI0408897A (en) |
CA (1) | CA2520405A1 (en) |
CL (1) | CL2004000639A1 (en) |
EA (1) | EA200501376A1 (en) |
EC (1) | ECSP056040A (en) |
GT (1) | GT200400050A (en) |
HR (1) | HRP20050859A2 (en) |
MA (1) | MA27828A1 (en) |
MX (1) | MXPA05010456A (en) |
NL (1) | NL1025839C2 (en) |
NO (1) | NO20054989L (en) |
OA (1) | OA13153A (en) |
PA (1) | PA8598901A1 (en) |
PE (1) | PE20050389A1 (en) |
TN (1) | TNSN05243A1 (en) |
TW (1) | TWI285641B (en) |
UY (1) | UY28243A1 (en) |
WO (1) | WO2004085401A1 (en) |
ZA (1) | ZA200507819B (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2295816T3 (en) | 2003-01-14 | 2008-04-16 | Arena Pharmaceuticals, Inc. | ARILO AND HETEROARILO 1,2,3-TRISUSTITUTED DERIVATIVES AS METABOLISM MODULATORS, AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THE SAME, SUCH AS DIABETES AND HYPERGLUCEMIA. |
SI3889142T1 (en) | 2003-04-11 | 2022-10-28 | Ptc Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
CA2532971A1 (en) | 2003-07-14 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
US20070149567A1 (en) * | 2004-09-23 | 2007-06-28 | Pfizer Inc | Quinoline compounds |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
AR051780A1 (en) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | FUSIONED RING COMPOUNDS CONTAINING NITROGEN AND USING THEMSELVES |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
KR20070114762A (en) * | 2005-02-24 | 2007-12-04 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
US7888376B2 (en) * | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
PE20071025A1 (en) * | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | TRISUSTITUTED AMINE COMPOUND |
US7745477B2 (en) * | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
UY30244A1 (en) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | A PROCESS TO PREPARE DERIVATIVES OF TETRAHYDROQUINOLINE |
KR101172120B1 (en) | 2006-05-10 | 2012-08-10 | 노파르티스 아게 | Bicyclic derivatives as cetp inhibitors |
US20080305169A1 (en) * | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
JP4108729B2 (en) * | 2006-05-26 | 2008-06-25 | 日本たばこ産業株式会社 | Nitrogen-containing fused ring compound-containing pharmaceutical composition |
WO2008058967A1 (en) * | 2006-11-15 | 2008-05-22 | Novartis Ag | Organic compounds |
JP4846769B2 (en) * | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | Pharmaceutical composition |
AU2008293542B9 (en) | 2007-08-27 | 2014-08-07 | Dart Neuroscience (Cayman) Ltd. | Therapeutic isoxazole compounds |
BRPI0919648A2 (en) | 2008-10-29 | 2015-12-08 | Hoffmann La Roche | new phenyl amide or pyridyl amide derivatives and their use as gpbar1 agonists |
US8420647B2 (en) | 2010-01-21 | 2013-04-16 | Hoffmann-La Roche Inc. | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9422281B2 (en) | 2013-11-18 | 2016-08-23 | Forma Therapeutics, Inc. | Benzopiperazine compositions as BET bromodomain inhibitors |
AU2014348191B2 (en) | 2013-11-18 | 2019-03-28 | Forma Therapeutics Inc. | Tetrahydroquinoline compositions as BET bromodomain inhibitors |
US9873677B2 (en) | 2014-03-06 | 2018-01-23 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
NZ734220A (en) | 2015-01-06 | 2022-01-28 | Arena Pharm Inc | Methods of treating conditions related to the s1p1 receptor |
MA42807A (en) | 2015-06-22 | 2018-07-25 | Arena Pharm Inc | SALT L-ARGININE CRYSTALLINE ACID (R) -2- (7- (4-CYCLOPENTYL-3- (TRIFLUOROMETHYL) BENZYLOXY) -1,2,3,4-TETRAHYDROCYCLO-PENTA [B] INDOL-3-YL) ACETIC (COMPOUND 1) FOR USE IN CONDITIONS ASSOCIATED WITH THE S1P1 RECEIVER |
CN108348527A (en) | 2015-10-30 | 2018-07-31 | Ptc医疗公司 | Method for treating epilepsy |
KR20190116416A (en) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | Compounds and Methods for Treating Primary Bile Cholangitis |
CN110452183B (en) * | 2019-09-04 | 2023-03-14 | 中国科学院上海有机化学研究所 | Preparation method of chiral heterocyclic compound |
CN111440162A (en) * | 2020-04-01 | 2020-07-24 | 邱曲真 | Thiazole dihydronaphthalene derivative and application thereof in metabolic diseases |
CN114656406B (en) * | 2022-01-25 | 2023-09-05 | 阿里生物新材料(常州)有限公司 | Synthesis method of 2-fluoropyrimidine-4-carboxylic acid |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE351464C (en) * | 1917-12-18 | 1922-04-07 | Chemische Werke Grenzach Aktie | Process for the preparation of derivatives of a hydrogenated 2-phenylquinoline-4-carboxylic acid |
EP1043326A1 (en) * | 1994-12-22 | 2000-10-11 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
JP2001503411A (en) * | 1996-10-28 | 2001-03-13 | ディパートメント オブ ジ アーミー,ユー.エス.ガバメント | Compounds, compositions and methods for the treatment of antibiotic resistant infections |
US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
DE69908555T2 (en) * | 1998-01-26 | 2004-05-06 | Smithkline Beecham P.L.C., Brentford | CHINOLINE DERIVATIVES AS AN ANTIBACTERIAL MEDICINAL PRODUCT |
GT199900147A (en) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED. | |
CO5271716A1 (en) * | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED |
-
2004
- 2004-03-15 EA EA200501376A patent/EA200501376A1/en unknown
- 2004-03-15 AU AU2004224082A patent/AU2004224082A1/en not_active Abandoned
- 2004-03-15 OA OA1200500269A patent/OA13153A/en unknown
- 2004-03-15 MX MXPA05010456A patent/MXPA05010456A/en unknown
- 2004-03-15 CN CNA2004800146455A patent/CN1795177A/en active Pending
- 2004-03-15 KR KR1020057018383A patent/KR100729883B1/en not_active IP Right Cessation
- 2004-03-15 BR BRPI0408897-2A patent/BRPI0408897A/en not_active IP Right Cessation
- 2004-03-15 CA CA002520405A patent/CA2520405A1/en not_active Abandoned
- 2004-03-15 JP JP2006506369A patent/JP2006521344A/en active Pending
- 2004-03-15 EP EP04720668A patent/EP1622872A1/en not_active Withdrawn
- 2004-03-15 WO PCT/IB2004/000836 patent/WO2004085401A1/en active Application Filing
- 2004-03-23 GT GT200400050A patent/GT200400050A/en unknown
- 2004-03-25 CL CL200400639A patent/CL2004000639A1/en unknown
- 2004-03-25 UY UY28243A patent/UY28243A1/en not_active Application Discontinuation
- 2004-03-26 NL NL1025839A patent/NL1025839C2/en not_active IP Right Cessation
- 2004-03-26 PE PE2004000323A patent/PE20050389A1/en not_active Application Discontinuation
- 2004-03-26 TW TW093108314A patent/TWI285641B/en not_active IP Right Cessation
- 2004-03-26 AR ARP040101024A patent/AR044507A1/en unknown
- 2004-03-26 PA PA20048598901A patent/PA8598901A1/en unknown
-
2005
- 2005-09-26 EC EC2005006040A patent/ECSP056040A/en unknown
- 2005-09-27 ZA ZA200507819A patent/ZA200507819B/en unknown
- 2005-09-28 MA MA28519A patent/MA27828A1/en unknown
- 2005-09-28 TN TNP2005000243A patent/TNSN05243A1/en unknown
- 2005-09-28 HR HR20050859A patent/HRP20050859A2/en not_active Application Discontinuation
- 2005-10-26 NO NO20054989A patent/NO20054989L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2004085401A1 (en) | 2004-10-07 |
HRP20050859A2 (en) | 2006-02-28 |
NL1025839C2 (en) | 2006-09-06 |
OA13153A (en) | 2006-12-13 |
TW200508222A (en) | 2005-03-01 |
UY28243A1 (en) | 2004-11-08 |
AU2004224082A1 (en) | 2004-10-07 |
KR20050115938A (en) | 2005-12-08 |
NO20054989L (en) | 2005-12-16 |
MA27828A1 (en) | 2006-04-03 |
JP2006521344A (en) | 2006-09-21 |
ECSP056040A (en) | 2006-01-27 |
WO2004085401A8 (en) | 2005-12-01 |
AR044507A1 (en) | 2005-09-14 |
CA2520405A1 (en) | 2004-10-07 |
CN1795177A (en) | 2006-06-28 |
TNSN05243A1 (en) | 2007-06-11 |
PE20050389A1 (en) | 2005-05-30 |
NO20054989D0 (en) | 2005-10-26 |
TWI285641B (en) | 2007-08-21 |
EA200501376A1 (en) | 2006-04-28 |
BRPI0408897A (en) | 2006-04-18 |
KR100729883B1 (en) | 2007-06-18 |
EP1622872A1 (en) | 2006-02-08 |
CL2004000639A1 (en) | 2005-02-04 |
GT200400050A (en) | 2005-03-02 |
NL1025839A1 (en) | 2004-09-30 |
MXPA05010456A (en) | 2006-03-21 |
ZA200507819B (en) | 2007-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8598901A1 (en) | QUINOLINE AND QUINOXALINE COMPOUND | |
SV2003000886A (en) | PPAR AGONISTS REF. PC11023AADO / BB | |
CR9089A (en) | COMPOUNDS AND DERIVATIVES OF DIBENCIL AMINA | |
DOP2007000044A (en) | DIBENCILAMINE COMPOUNDS AND DERIVATIVES | |
CR9012A (en) | 4-AMINO-SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINE COMPOUNDS | |
UY28097A1 (en) | PPAR ACTIVATORS | |
PA8539101A1 (en) | PPAR COMPOUNDS | |
UY29124A1 (en) | QUINOLINE COMPOUNDS | |
EA200801815A1 (en) | DIBENZYLAMINUM COMPOUNDS AND DERIVATIVES | |
BRPI0607839A2 (en) | substituted 1,1,1-trifluoro-3 - [(benzyl) - (pyrimidin-2-yl) amino] propan-2-ol compounds | |
SV2006002314A (en) | COMPOUNDS AND DERIVATIVES OF DIBENCIL AMINA REF. NO. PC32592A | |
DOP2004000863A (en) | QUINOLINE AND QUINOXALINE COMPOUNDS | |
DOP2005000179A (en) | QUINOLINE COMPOUND | |
PA8589501A1 (en) | PPAR ACTIVATORS | |
DOP2003000762A (en) | PPAR ACTIVATORS | |
DOP2002000327A (en) | PPAR AGONISTS | |
ECSP088730A (en) | DIBENCILAMINE DERIVATIVES AS CETP INHIBITORS | |
DOP2005000238A (en) | COMPOUNDS AND DERIVATIVES OF DIBENCIL AMINA | |
UY27168A1 (en) | PPAR AGONISTS | |
CU20080164A7 (en) | DIBENCILAMINE COMPOUNDS AND DERIVATIVES | |
UY29123A1 (en) | 4-AMINO-SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINE COMPOUNDS | |
DOP2002000331A (en) | PPAR COMPOUND | |
UY27158A1 (en) | PPAR COMPOUNDS | |
UY29539A1 (en) | MEK HETEROCICLIC INHIBITORS AND SAME USE METHODS | |
DOP2005000182A (en) | 4-AMINO-SUBSTITUTED-2-SUBSTITUTED-1,2,3-TETRAHYDROQUINOLINE COMPOUNDS |